TOKYO–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan. The Impella 2.5 and Impella 5.0 heart pumps are approved for the treatment of drug-resistant acute heart failure and are the first and only percutaneous temporary ventricular support devices Pharmaceuticals and Medical Devices Agency (PMDA) approved in Japan. Impella is a minimally invasive therapy that takes over the pumping function of the heart, pumping blood around the body while the heart rests and recovers.
The first patient in Japan was successfully treated in October 2017 with the Impella 5.0 heart pump at Osaka University Hospital under the leadership of Professor Yoshiki Sawa, M.D., Ph.D. of the Department of Cardiovascular Surgery, Osaka University’s Graduate School of Medicine. Since then, more than 100 hospitals across Japan can now provide Impella support to patients and 138 hospitals have been approved by the government and the Circulatory Support Committee.
Of the first 1,000 Japanese cases, procedural outcomes data is available on the first 580 cases1). The data demonstrates improvements in AMI cardiogenic shock and myocarditis survival rates during the procedure, compared to traditional therapies:
AMI Cardiogenic Shock:
- %
